BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 35120267)

  • 1. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience.
    Verderese JP; Stepanova M; Lam B; Racila A; Kolacevski A; Allen D; Hodson E; Aslani-Amoli B; Homeyer M; Stanmyre S; Stevens H; Garofalo S; Henry L; Venkatesan C; Gerber LH; Motew SJ; Jones JS; Younossi ZM
    Clin Infect Dis; 2022 Mar; 74(6):1063-1069. PubMed ID: 34166513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
    Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
    Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab.
    Heller M; Henrici C; Büttner J; Leube S; Treske I; Pospischil P; Doll M; Schanz I; Hallier A; Herrmann E; Schmidt M; Sarrazin C
    Int J Infect Dis; 2023 Apr; 129():260-265. PubMed ID: 36690138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
    Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
    J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
    O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
    JAMA; 2022 Feb; 327(5):432-441. PubMed ID: 35029629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to "successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience": A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era.
    Cassin R; Rampi N; C F; Muscatello A; Mariani B; Noto A; Rossi FG; Baldini L
    Hematol Oncol; 2023 Feb; 41(1):213-217. PubMed ID: 36156809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
    Ambrose N; Amin A; Anderson B; Barrera-Oro J; Bertagnolli M; Campion F; Chow D; Danan R; D'Arinzo L; Drews A; Erlandson K; Fitzgerald K; Garcia M; Gaspar FW; Gong C; Hanna G; Jones S; Lopansri B; Musser J; O'Horo J; Piantadosi S; Pritt B; Razonable RR; Roberts S; Sandmeyer S; Stein D; Vahidy F; Webb B; Yttri J
    JAMA Netw Open; 2023 Apr; 6(4):e239694. PubMed ID: 37093599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.
    Siemieniuk RA; Bartoszko JJ; Díaz Martinez JP; Kum E; Qasim A; Zeraatkar D; Izcovich A; Mangala S; Ge L; Han MA; Agoritsas T; Arnold D; Ávila C; Chu DK; Couban R; Cusano E; Darzi AJ; Devji T; Foroutan F; Ghadimi M; Khamis A; Lamontagne F; Loeb M; Miroshnychenko A; Motaghi S; Murthy S; Mustafa RA; Rada G; Rochwerg B; Switzer C; Vandvik PO; Vernooij RW; Wang Y; Yao L; Guyatt GH; Brignardello-Petersen R
    BMJ; 2021 Sep; 374():n2231. PubMed ID: 34556486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    O'Horo J; Challener DW; Anderson RJ; Arndt RF; Ausman SE; Hall ST; Heyliger A; Kennedy BD; Sweeten PW; Ganesh R; Razonable RR
    Mayo Clin Proc; 2022 May; 97(5):943-950. PubMed ID: 35512884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
    McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Nakayama A; Zapf RL; Kip PL; Seymour CW; Huang DT
    Contemp Clin Trials; 2022 Aug; 119():106822. PubMed ID: 35697146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
    Miyazato Y; Yamamoto K; Nakaya Y; Morioka S; Takeuchi JS; Takamatsu Y; Maeda K; Kimura M; Sugiura W; Mitsuya H; Yano M; Ohmagari N
    J Infect Chemother; 2022 Jul; 28(7):991-994. PubMed ID: 35337728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic monoclonal antibodies for COVID-19 management: an update.
    Chavda VP; Prajapati R; Lathigara D; Nagar B; Kukadiya J; Redwan EM; Uversky VN; Kher MN; Patel R
    Expert Opin Biol Ther; 2022 Jun; 22(6):763-780. PubMed ID: 35604379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
    Bronstein Y; Adler A; Katash H; Halutz O; Herishanu Y; Levytskyi K
    J Med Virol; 2022 Mar; 94(3):1241-1245. PubMed ID: 34755363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.